Author Question: The nurse is teaching a class on dietary supplements. The nurse determines that learning has ... (Read 56 times)

yoroshambo · **on:** Jul 23, 2018

The nurse is teaching a class on dietary supplements. The nurse determines that learning has occurred when the patients make which statement?

1. Products can make claims based on body structure and function like promotes healthy urinary tract.'
2. Dietary supplements must go through rigorous testing prior to being marketed by the manufacturer.
3. The Food and Drug Administration (FDA) is not involved with the approval of the dietary supplement and cannot remove it from the market.
4. The manufacturer of the dietary supplement has the burden of proof for the safety of the supplement.

Question 2

The patient uses Ginkgo biloba to enhance memory functioning, but has not told the nurse about this herb. The physician orders warfarin (Coumadin) for the patient. What will the best assessment of the nurse include?

1. Headache, dizziness, sweating, and agitation
2. A blood glucose of 56
3. An international normalized ratio (INR) of 3.0
4. Petechiae and bleeding from the gums

softEldritch · **Reply #1 on:** Jul 23, 2018

Answer to Question 1

Correct Answer: 1
Rationale: The Dietary Supplement Health and Education Act (DSHEA) of 1994 states that the supplement label may make claims about the product's effect on body structure and function such as promotes healthy urinary tract. The Dietary Supplement Health and Education Act (DSHEA) of 1994 states that the government has the responsibility to prove that the dietary supplement is unsafe. The Dietary Supplement Health and Education Act (DSHEA) of 1994 states that dietary supplements do not have to be tested prior to marketing. The Dietary Supplement Health and Education Act (DSHEA) of 1994 states that the Food and Drug Administration (FDA) has the power to remove from the market any product that poses a significant or unreasonable risk to the public.

Answer to Question 2

Correct Answer: 4
Rationale: Ginkgo biloba will interact with warfarin (Coumadin) to promote increased bleeding potential that may lead to petechiae and bleeding from the gums. An international normalized ratio (INR) of 3.0 is within a normal range. Hypoglycemia, (blood glucose of 56), is not the result of an interaction between Ginkgo biloba and warfarin (Coumadin). Headache, dizziness, sweating, and agitation, which are signs of serotonin syndrome, are not the result of an interaction between Ginkgo biloba and warfarin (Coumadin).